Table 3 Demographics of patients in the advanced/metastatic setting after stratification by age.
From: Imatinib use for gastrointestinal stromal tumors among older patients in Japan and Taiwan
Demographics | JCR database | p value | TCR database | p value | ||||||
|---|---|---|---|---|---|---|---|---|---|---|
< 75 | ≥ 75 | < 75 | ≥ 75 | |||||||
(n = 181) | (n = 54) | (n = 297) | (n = 104) | |||||||
Male | 116 | (64.1) | 33 | (61.1) | 0.690 | 190 | (64.0) | 59 | (56.7) | 0.190 |
Age (median [IQR], years) | 63 | (55, 69) | 79.0 | (77, 82) | 58 | (50, 65) | 81 | (77, 85) | ||
Tumor size (cm)a | 0.666 | 0.300 | ||||||||
≤ 5 | 34 | (18.8) | 11 | (20.4) | 24 | (8.0) | 12 | (11.6) | ||
> 5– ≤ 10 | 56 | (30.9) | 23 | (42.6) | 48 | (16.2) | 19 | (18.3) | ||
> 10 | 54 | (29.8) | 16 | (29.6) | 83 | (27.9) | 20 | (19.2) | ||
Mitosis | 0.120 | |||||||||
Low | – | – | – | – | 39 | (13.1) | 11 | (10.6) | ||
High | – | – | – | – | 107 | (36.0) | 28 | (26.9) | ||
Unknown | – | – | – | – | 151 | (50.8) | 65 | (62.5) | ||
Stagea | 0.873 | 0.005 | ||||||||
I | 14 | (7.7) | 4–6b | 4 | (1.3) | 7 | (6.7) | |||
II | 22 | (12.2) | 7–9b | 19 | (6.4) | 7 | (6.7) | |||
III | 40 | (22.1) | 14 | (25.9) | 40 | (13.5) | 21 | (20.2) | ||
IV | 81 | (44.8) | 23 | (42.6) | 116 | (39.1) | 26 | (25.0) | ||
Distant metastasis | 0.334 | 0.020 | ||||||||
Yes | 87 | (48.1) | 22 | (40.7) | 116 | (39.1) | 25 | (24.0) | ||
Year of diagnosis | 0.637 | 0.148 | ||||||||
2012 | 37 | (20.4) | 13 | (24.1) | 98 | (33.0) | 40 | (38.5) | ||
2013 | 71 | (39.2) | 23 | (42.6) | 99 | (33.3) | 24 | (23.1) | ||
2014 | 73 | (40.3) | 18 | (33.3) | 100 | (33.7) | 40 | (38.5) | ||
Primary site | 0.100 | 0.166 | ||||||||
Stomach | 69 | (38.1) | 28 | (51.9) | 123 | (41.4) | 47 | (45.2) | ||
Small intestine/duodenum | 71 | (39.2) | 13 | (24.1) | 109 | (36.7) | 28 | (26.9) | ||
Others | 41 | (22.7) | 13 | (24.0) | 65 | (21.9) | 29 | (27.9) | ||
Treatment group | 0.012 | < 0.001 | ||||||||
Continued | 56 | (30.9) | 22 | (40.7) | 46 | (15.5) | 10 | (9.6) | ||
Discontinued | 41 | (22.7) | 19 | (35.2) | 91 | (30.6) | 65 | (62.5) | ||
Switched | 84 | (46.4) | 13 | (24.1) | 160 | (53.9) | 29 | (27.9) | ||
Treatment group | 0.076 | < 0.001 | ||||||||
Continued + switched | 140 | (77.3) | 35 | (64.8) | 206 | (69.4) | 39 | (37.5) | ||
Discontinued | 41 | (22.7) | 19 | (35.2) | 91 | (30.6) | 65 | (62.5) | ||
Time to stop imatinib, days | ||||||||||
Median, 95% CI | 542 | (416, 694) | 423 | (196, 752) | 884 | (683, 1021) | 366.5 | (272, 491) | ||
Starting dosage (imatinib, mg) | < 0.001 | < 0.001 | ||||||||
≤ 300 | 13 | (7.2) | 16 | (29.6) | 24 | (8.1) | 34 | (32.6) | ||
≥ 400 | 168 | (92.8) | 38 | (70.4) | 273 | (91.9) | 70 | (67.3) | ||
Imatinib dose over the entire treatment period (median [IQR], mg/day) | 400 | (300, 400) | 300 | (200, 300) | < 0.001 | 400 | (400, 400) | 400 | (300, 400) | < 0.001 |
Survival status during the follow-up period | < 0.001 | |||||||||
Alive | – | – | – | – | 158 | 53.2 | 23 | 22.1 | ||
Dead | – | – | – | – | 139 | 46.8 | 81 | 77.9 | ||
Median survival time, days | 1965 | 815 | ||||||||
